Solutions
About Us
Insights
Careers

Progression-free survival as a surrogate endpoint for overall survival in patients with relapsed or refractory multiple myeloma. Dimopoulos M, Sonneveld P, Manier S, Lam A, Roccia T, Schecter JM, Cost P, Pacaud L, Poirier A, Tremblay G, Lan T, Valluri S, Kumar S., BMC Cancer. 2024

Real-world experience with filgotinib for rheumatoid arthritis in Germany : A retrospective chart review. Schultz O, Fiehn C, Kneitz C, Picker N, Kromer D, Zignani M, De Leonardis F, Orzechowski HD, Gurrath M, Krüger K. Z, Rheumatol. 2024

Impact of patient support programmes among patients with severe asthma treated with biological therapies: a systematic literature review and indirect treatment comparison. Rabe APJ, Loke WJ, Kielar D, Morris T, Shih VH, Olinger L, Musat MG, Lan Z, Harricharan S, Fulton O, Majeed A, Heaney LG., BMJ Open Respir Res. 2024

Editorial: Novel methods and technologies for the evaluation of drug outcomes and policies. Adamson B, Makady A, Sarri G, Mohamed O, Babar Z, Dawoud DM., Front Pharmacol. 2024

Prospective benchmarking of an observational analysis in the SWEDEHEART registry against the REDUCE-AMI randomized trial. Matthews AA, Dahebreh IJ, MacDonald CJ, Lindahl B, Hofmann R, Erlinge D, Yndigegn T, Berglund A, Jernberg T, Hernán MA., Eur J Epidemiol. 2024

Opportunity and accessibility: an environmental scan of publicly available data repositories to address disparities in healthcare decision-making. Vinals L, Radhakrishnan A, Sarri G., Int J Equity Health. 2024

A Post-Marketing Surveillance Study of Nusinersen for Spinal Muscular Atrophy in Routine Medical Practice in China: Interim Results. Jiang Y, Wang Y, Xiong H, Li W, Luo R, Chen W, Yin F, Lü J, Liang J, Chen WJ, Lu X, Wang H, Tang J, Monine M, Makepeace C, Jin X, Foster R, Chin R, Berger Z., Adv Ther. 2024

Cost-effectiveness of PCV20 to Prevent Pneumococcal Disease in the Pediatric Population: A German Societal Perspective Analysis. Ta A, Kühne F, Laurenz M, von Eiff C, Warren S, Perdrizet., J. Infect Dis Ther. 202

Immunogenicity and safety of Ad26.RSV.preF/RSV preF protein vaccine at predicted intermediate- and end-of-shelf-life as an evaluation of potency throughout shelf life. Hosman T, van Heesbeen R, Bastian AR, Hu W, Comeaux C, Ligtenberg N, van Montfort B, Callendret B, Heijnen E., Hum Vaccin Immunother. 2024

Seasonal human coronavirus humoral responses in AZD1222 (ChaAdOx1 nCoV-19) COVID-19 vaccinated adults reveal limited cross-immunity. Stanley AM, Aksyuk AA, Wilkins D, Green JA, Lan D, Shoemaker K, Tieu HV, Sobieszczyk ME, Falsey AR, Kelly EJ., Front Immunol. 2024